FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

The FDA said Wednesday that it is investigating "serious risk of hematologic malignancy" following the administration of bluebird bio's Skysona, a gene therapy approved for the rare disease known as cerebral ...